ASSESSMENT OF SERUM TENASCIN-C AND GROWTH DIFFERENTIATION FACTOR-15 AMONG TYPE 2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROME
Abstract
Background: High prevalence of type 2 diabetes mellitus (T2DM) is associated with a higher prevalence of acute coronary syndrome (ACS). Inflammation is one of the important contributors to the pathogenesis and complications of coronary atherosclerotic plaque. Growth Differentiation Factor-15 (GDF-15) and Tenascin-C (TNC) play an important role in the initiation of atherosclerotic plaque as well as its rupture. The aim of the study was to evaluate the association between serum GDF-15, TNC, and the risk of ACS among T2DM patients. Methods: Anthropometric parameters, routine biochemical investigations like liver and renal function tests, lipid profile, and Creatine Kinase-Total (CK-T), Creatine Kinase-MB (CK-MB) were measured in 42 T2DM patients with ACS and 42 T2DM patients. Serum GDF-15 and TNC were measured by Human Sandwich-ELISA kits. Results: Serum GDF-15 and TNC levels were significantly higher in T2DM patients with ACS as compared to T2DM patients. Serum GDF-15 was significantly correlated with waist circumference, diastolic blood pressure,pulse, serum CK-T, and CK-MB. Serum TNC was significantly correlated with the pulse, serum CK-T, CK-MB, high- density lipoprotein-cholesterol, and blood urea nitro gen. Multivariate linear regression analysis showed that waist circumference was independently positively associated with serum GDF-15. Conclusions: T2DM patients with higher serum GDF-15 and TNC levels were at higher risk of acute coronary syndrome independent of other cardiovascular risk factors. Keywords: type 2 diabetes mellitus, acute coronary syndrome, tenascin-C, growth differentiation factor-15.
References
Kashyap SR, Gatmaitan P, Brethauer S, Schauer P. Bariatric surgery for type 2 diabetes: Weighing the impact for obese patients. Cleve Clin J Med 2010; 77(7):468–76.
Sethi SS, Akl EG, Farkouh ME. Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials. Curr Diab Rep 2012; 12(3): 294–304.
Tzikas S, Palapies L, Bakogiannis C, Zeller T, Sinning C, Baldus S, et al. GDF-15 predicts cardiovascular events in acute chest pain patients. Zirlik A, editor. PLoS One. 2017; 12(8): e0182314.
Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 2004; 68(3): 198–203.
Sakamoto N, Hoshino Y, Misaka T, Mizukami H, Suzuki S, Sugimoto K, et al. Serum tenascin- C level is associated with coronary plaque rupture in patients with acute coronary syndrome. Heart Vessels 2014; 29(2): 165–70.
Arican Ozluk O, Topal D, Tenekecioglu E, Peker T, Yilmaz M, Karaagac K, et al. High tenascin-C levels cause inadequate myocardial blush grade in patients with acute myocardial infarction. Int J Clin Exp Med 2015; 8(2):2554–61.
Yang JH, Ren F. Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome. Biomed Rep 2014; 2(1): 132–6.
Franz M, Jung C, Lauten A, Figulla HR, Berndt A. Tena - scin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy. Cell Adh Migr 2015; 9(1–2): 90–5.
Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, et al. Growth- differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30(19): 2346–53.
Popovic D, Lalic K, Jotic A, Milicic T, Bogdanovic J, Đorđevic M, Stankovic S, Jeremic V, Lalic NM. The inflammatory and hemostatic cardiovascular risk markers during acute hyperglycemic crisis in type 1 and type 2 diabetes. J Med Biochem 2019; 38: 126–33.
Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 2012; 17(5):671–8.
Bego T, ^au{evi} A, Duji} T, Malenica M, Velija-Asimi Z, Prnjavorac B, Marc J, Nekvindová J, Pali~ka V, Semiz S. Association of FTO gene variant (rs8050136) with type
diabetes and markers of obesity, glycaemic control and inflammation. J Med Biochem 2019; 38: 153–63.
Aswathy JS, Adole PS, Wyawahare M, RamPrakasha S. Assessment of Serum Vaspin Levels among Type 2 Diabetes Mellitus Patients with or without Acute Coronary Syndrome. J Clin Diagn Res 2016; 10(12):BC07–BC10.
Unuvar S, Tanrıverdi Z, Aslanhan H. Potential prognostic role of immune system activation marker neopterin in patients with type 2 diabetes. J Med Biochem 2018; 37: 465–9.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014; 114(6): 890–4.
Li H, Gao F, Xue Y, Qian Y. Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy. Nan Fang Yi Ke Da Xue Xue Bao 2014; 34(3): 387–90.
Schopfer DW, Ku IA, Regan M, Whooley MA. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J 2014; 167(2): 186–92.
Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, et al. Growth differentiation factor- 15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009; 30(9): 1057–65.
Zhang S, Dai D, Wang X, Zhu H, Jin H, Zhao R, et al. Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord 2016; 16: 82.
Gaber R, Ibrahim WS, Nofal HE, Mahran DS. Value of serum tenascin-C in patients with acute myocardial infarction. Alex J Med 2016; 52(3): 227–33.
Copyright (c) 2020 Murugaiyan Vasanthi, Prashant Shankarrao Adole, Vinay Ramakrishna Pandit, Kolar Vishwanath Vinod
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.